Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Aug 2026

Paksoy Barıs, Erkal Ozgur, Kocaaga Ayca

Abstract excerpt

BACKGROUND: Targeted multigene panel testing is increasingly used to assess hereditary cancer susceptibility beyond BRCA1/2. However, the distribution and clinical significance of pathogenic variants and variants of uncertainsignificance (VUS) in non-BRCA1/2 genes remain incompletely characterized. METHODS: In this retrospective study, 647 individuals referred for hereditary cancer genetic testing were analyzed....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 2

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Prostatic Neoplasms

Share to Turkey

Source

Identifiers

PMID: 41697532
DOI: 10.1007/s12094-026-04258-z

Genes

BRCA1
ATM
CHEK2
MUTYH
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort.PMID 41697532Read ↗

Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients.Semantic proximity Read ↗

Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing.Semantic proximity Read ↗

Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controlsSemantic proximity Read ↗

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.Semantic proximity Read ↗

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.Semantic proximity Read ↗

Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.Semantic proximity Read ↗

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.Semantic proximity Read ↗

Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.Semantic proximity Read ↗

Germline variant spectrum of hereditary cancer susceptibility genes in a Chinese cohort.Semantic proximity Read ↗

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.Semantic proximity Read ↗

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.Semantic proximity Read ↗

Analysis of BRCA1/2 variants of unknown significance in patients with breast cancer from a prospective KOHBRA studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.